Related Experiment Video
Updated: Oct 3, 2025
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Combined effect of heterogeneous target dose and heterogeneous radiosensitivity on tumor control probability for
V Y Kuperman1, L M Lubich2, Gregory S Spradlin3
1Medical Physics Support, Inc., Tampa, FL 33634, USA.
Purpose:
To evaluate the combined effect of heterogeneous target dose and heterogeneous radiosensitivity on tumor control probability (TCP) for different number of fractions (Nf).
Methods:
The linear-quadratic (LQ) model is employed to study dependence of TCP on Nf under the condition of fixed nominal biologically effective dose (BEDnom).
Results:
Formula for the optimum target dose which maximizes TCP under the condition BEDnom=const is analytically derived. It is shown that the dependence of TCP on Nfis non-monotonic. In addition, the dependence of TCP on Nf for different variances of the target dose and radiosensitivity of malignant cells is demonstrated by using numerical computations.
Conclusions:
It is shown that the optimum mean dose in the target is defined by the standard deviations of the target dose (σD) and standard deviations of parameters alpha (σα) and beta (σβ). The findings of this study indicate that hypofractionated regimens for stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) with Nf⩽3 can be radiobiologically inferior to the regimens with five or more fractions.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...